Although higher rates of rash-associated hepatotoxicity were observed among Thai women, other studies have also observed high rates of nevirapine-associated rash in Thailand [44]. Thirdly, we do not have data on exposure to other hepatotoxins (e.g. alcohol and chronic aflatoxin exposure Sunitinib concentration [36,45]). Fourthly, few women (n=7) in this study had CD4 counts ≥350 cells/μL and therefore these findings cannot necessarily be extrapolated to women with higher (≥350 cells/μL) CD4 counts. Finally, we have not evaluated whether chronic hepatitis B virus (HBV) coinfection might have augmented or confounded

the associations we observed between abnormal baseline serum transaminases and risk of hepatitis after initiating nevirapine. Although the presence of HBV surface antigen alone has not been associated with increased risk of hepatotoxicity [46], HBV DNA levels >2000 copies/mL have been found among persons taking antiretrovirals [47]. In summary, severe hepatotoxicity and rash-associated hepatotoxicity occurred in 3–5% of women in three resource-limited settings during the first 24 weeks after initiating therapy with www.selleckchem.com/products/obeticholic-acid.html nevirapine-based ART. Risk for both outcomes was predicted by abnormal baseline transaminase levels but not by a CD4 count ≥250 cells/μL. Although we observed alterations in the risk of rash-associated hepatotoxicity by CD4 count, risk was equivalently elevated at CD4 counts <50 and ≥200 cells/μL. In resource-limited settings where transaminase

testing is available, laboratory evaluation for hepatotoxicity should focus on women with baseline transaminase abnormalities regardless of CD4 cell count and on early time-points after nevirapine initiation. In addition, clinical vigilance and patient education to minimize concomitant exposure to nevirapine

Vasopressin Receptor and other hepatotoxins should be emphasized. Clinicians and public health officials should be aware that limiting nevirapine use to women with a CD4 count <250 cells/μL may not limit the frequency of nevirapine-associated hepatotoxicity events but may reduce treatment options unnecessarily. This publication was made possible by support from the President’s Emergency Plan for AIDS Relief (PEPFAR), from the Department of Health and Human Services (DHHS)/Centers for Disease Control and Prevention (CDC), Global AIDS Program and from the Division of HIV/AIDS Prevention, CDC. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the CDC. Conflict of interest None of the authors reports a conflict of interest. Funding In Zambia, this study was supported by grant U62/CCU12354 from the US CDC, with complementary funding from the University of Alabama at Birmingham (UAB). In Thailand, this study was supported by the US CDC through purchase orders #Bangkok-07-M-0424 to the Department of Pediatrics, Faculty of Medicine, Siriraj Hospital, Mahidol University and #Bangkok-07-M-0425 to Rajavithi Hospital.

No related posts.